Feasibility of Quantitative Magnetic Resonance Fingerprinting in Ovarian Tumors for T<sub>1</sub> and T<sub>2</sub> Mapping in a PET/MR Setting.

Thumbnail
View / Open Files
Authors
  Kaggie, Joshua
  Deen, Surrin
  Kessler, Dimitri
  McLean, Mary
  Buonincontri, Guido
Schulte, Rolf F
Addley, Helen
Publication Date
2019-07
Journal Title
IEEE transactions on radiation and plasma medical sciences
ISSN
2469-7311
Volume
3
Issue
4
Pages
509-515
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item record
Citation
Kaggie, J., Deen, S., Kessler, D., McLean, M., Buonincontri, G., Schulte, R. F., Addley, H., et al. (2019). Feasibility of Quantitative Magnetic Resonance Fingerprinting in Ovarian Tumors for T<sub>1</sub> and T<sub>2</sub> Mapping in a PET/MR Setting.. IEEE transactions on radiation and plasma medical sciences, 3 (4), 509-515. https://doi.org/10.1109/trpms.2019.2905366
Abstract
Multi-parametric magnetic resonance imaging (MRI) can be used to characterise many cancer subtypes, including ovarian cancer. Quantitative mapping of MRI relaxation values, such as T1 and T2 mapping, is promising for improving tumour assessment beyond conventional qualitative T1- and T2-weighted images. However, quantitative MRI relaxation mapping methods often involve long scan times due to sequentially measuring many parameters. Magnetic Resonance Fingerprinting (MRF) is a new method that enables fast quantitative MRI by exploiting the transient signals caused by the variation of pseudorandom sequence parameters. These transient signals are then matched to a simulated dictionary of T1 and T2 values to create quantitative maps. The ability of MRF to simultaneously measure multiple parameters, could represent a new approach to characterising cancer and assessing treatment response. This feasibility study investigates MRF for simultaneous T1, T2 and relative proton density (PD) mapping using ovarian cancer as a model system.
Sponsorship
The authors acknowledge research support from the National Institute of Health Research Cambridge Biomedical Research Centre, GlaxoSmithKline.Cancer Research UK (CRUK), the CRUK Cambridge Centre, Medical Research Council, CRUK/Engineering and Physical Sciences Research Council Imaging Centre in Cambridge and Manchester, Addenbrooke's Charitable Trust, and the Cambridge Experimental Cancer Medicine Centre.
Funder references
Cancer Research UK (16465)
Cancer Research UK (CB4150)
Identifiers
External DOI: https://doi.org/10.1109/trpms.2019.2905366
This record's URL: https://www.repository.cam.ac.uk/handle/1810/290524

Rights